In S, Le Lann AD, Oksman F, Fournié EL, Labarre JF, Benoist H, Fournié GJ. An in vivo model for the experimental selection of drugs able to prevent immune complex glomerulonephritis.
INTERNATIONAL JOURNAL OF IMMUNOPHARMACOLOGY 1992;
14:871-6. [PMID:
1387391 DOI:
10.1016/0192-0561(92)90086-z]
[Citation(s) in RCA: 3] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 12/26/2022]
Abstract
Polyclonal activation of lymphocytes and immune complex-mediated glomerular lesions were induced in C57Bl/6 mice by injecting bacterial lipopolysaccharide (LPS) twice a week for 2 weeks. The usefulness of such a model for in vivo evaluation of immunomodulatory and therapeutic effects of drugs, was investigated by treating mice with DIAM4, a cyclophosphazenic compound known to modulate polyclonal activation of lymphocytes and to prevent mouse lupus nephritis. Prevention of LPS-triggered lymphocyte polyclonal activation and glomerular lesions was observed in the DIAM4-treated mice. Such a model can be used conveniently to select compounds effective in the treatment of immune glomerulonephritis.
Collapse